This powerful drug combo cuts prostate cancer deaths by 40%
8 Articles
8 Articles
This powerful drug combo cuts prostate cancer deaths by 40%
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 patients worldwide and was led by Cedars-Sinai researchers. Experts call it a game changer that’s likely to reshape treatment guidelines for aggressive prostate cancer.
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate...
ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA® plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
notizie.it
(Adnkronos) - The new 'late-breaking' data presented at Congress 2026 of the European Society of Medical Oncology (Esmo) show that "the addition of
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
